Both companies are experiencing rapid growth by providing cutting edge science and technical know-how to help create life changing human disease therapies. This partnership looks to enable the creation and delivery of new NK cell therapies for cancer patients.
About B-MoGen Biotechnologies, Inc.
BMoGen Biotechnologies, Inc. is a privately held genome engineering company providing expertise through disruptive, proprietary and cutting-edge gene delivery methods to enable faster research and more cost-effective therapies. B-MoGen partners with scientists and bio-therapeutics companies who create life-changing medicines for human disease. B-MoGen’s proprietary and available TcBusterTM technology is a non-viral transposon-based gene therapy platform to support the T-Cell immunotherapy industry that drives down the cost of CAR-T therapy for cancer and other diseases. B-MoGen is demonstrating genome engineering of the mitochondrial genome and is the first company in the world to engineer the mitochondrial genome in human cells with an exclusive license from Mayo Clinic for this technology. B-Mogen is on the cusp of editing and correcting specific mitochondria genetic mutations. B-MoGen also provides fee-for-service custom cell engineering of cell lines for cancer research, drug screening, and antibody validation.
Learn more about B-MoGen at bmogen.com
About CytoSen Therapeutics, Inc.
CytoSen is a private biopharmaceutical company on the front line of advancing clinical development of next generation NK cells with the first scalable, therapeutic platform for high dose, cancer-killing NK cells calibrated to each cancer target while reinforcing immune defenses.
Born from the intersection of cellular immunotherapy and nanotechnology, CytoSen’s NK cell therapy harnesses the power of the immune system to treat cancer.
Learn more about CytoSen at www.CytoSen.com/